MISSISSAUGA, Ontario--(BUSINESS WIRE)--Jan. 19, 2004--Hedley Technologies Inc. (TSX Venture: HED) announces it has signed distributors in Vietnam and the Philippines for the exclusive distribution rights of the INSTI(R) HIV Rapid Test Kit. As part of the Distributor Agreement, each Distributor is obliged to administer and assist in the registration and approval of the INSTI(R) within its territory. The regulatory approval process has commenced in both the Philippines and Vietnam.
“Given that the combined population of these two countries is over 165 million, and the respective governments’ commitment to HIV/AIDS education and awareness, we view this as an excellent opportunity to provide a quality product into areas that are taking an aggressive stance against the proliferation of HIV and AIDS,” said Rene Goehrum, Hedley’s Chairman and CEO. “With the assistance of these Distributors, we anticipate an expedited registration process which in turn will help us access the entire Pacific Rim area in a meaningful way and reduce the time to secure initial orders in these markets.”
The INSTI(R) HIV-1/HIV-2 Antibody Test is a rapid in vitro qualitative test for the detection of antibodies to Human Immunodeficiency Viruses Types 1 and 2 (collectively referred to as HIV-1/2) in human whole blood, serum or plasma. The test is intended for use by trained personnel in medical facilities, clinical laboratories, and emergency care situations as a point-of-care test capable of providing results in approximately sixty seconds.
Hedley Technologies Inc. is a publicly traded life science company that develops, acquires, or commercializes proprietary science-based technologies that advance human health, public safety and the value of agricultural production. Hedley’s common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol HED.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations and profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of same.
Contacts
Hedley Technologies, Inc. Rene C. Goehrum, 905-206-0013 Fax: 905-206-1413 rgoehrum@hedleytech.com or Joseph Arcuri, 905-206-0013 Fax: 905-206-1413 jarcuri@hedleytech.com www.hedleytech.com
